<DOC>
	<DOCNO>NCT01002430</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy catheter mediate endocardial adenovirus VEGF-D gene therapy patient severe coronary heart disease .</brief_summary>
	<brief_title>EndocardialVascularEndothelialGrowth Factor D ( VEGF-D ) Gene Therapy Treatment Severe Coronary Heart Disease</brief_title>
	<detailed_description>Study objective ( ) : The purpose study evaluate safety efficacy catheter mediate endocardial adenovirus VEGF-D gene transfer patient severe coronary heart disease revascularisation perform ( `` option -patients '' ) . The primary objective safety gene therapy secondary objective efficacy gene therapy improve myocardial perfusion measure MRI , PET leave ventricular function measure echocardiography well improve functional status measure bicycle ergometer test . Quality life monitor personal interview consumption nitrate medication . Study design : This randomise , single-blinded , placebo control single centre Phase I study patient coronary heart disease treatment standard medication available . Patients randomize 4:1 treatment group control group . Control patient treat gene injection cardiac electroanatomical mapping . Study population : Up thirty patient recruit area Kuopio University Hospital study . The patient select trial basis coronary angiogram imaging . Only patient eligible coronary angioplasty bypass operation ( `` option -patients '' ) due diffuse coronary stenosis , small coronary vessel , repeat revascularisation high risk operation , include . Assessments : Assessments safety record adverse event ( Appendix 4 ) , laboratory assessment transthoracic echocardiography . Assessments efficacy clinical symptom need nitrate medication , cardiac MRI , PET bicycle ergometer test . Other assessment 24-hour Holter recording , transthoracal echocardiography , quality life PCR reaction detection gene virus vector . Investigational drug product : First generation replication-deficient AdVEGF-D produce 293 cell ( refer product master file ( PMF-VD-08-001 ) ) inject ten site endocardium . In begin , escalate dose 1x109 , 1x1010 1x1011 vpu virus total volume 2 ml ( 10 time 0.2 ml ) use . On basis fifteen patient interim analysis perform evaluate suitable dose virus use rest study patient . Control patient treat drug product , electroanatomical mapping perform .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<criteria>informed consent sign , age 30 80 year , significant angina pectoris ( CCS IIIII ) despite maximal medication , significant stenosis coronary angiography ( stenosis &gt; 60 % ) , contraindication coronary angioplasty pas operation ( diffuse distal stenosis , chronic total occlusion , vessel difficult anatomy , stenosis severe calcification , stenosis small vessel ( &lt; 2.5 mm ) ) , reversible myocardial perfusion defect detect pharmacological adenosine dobutamine assist perfusion MRI , angina pectoris ischemic STdepression ( &gt; 1 mm ) exercise test , leave ventricle wall &gt; 8 mm detect transthoracal echocardiography ( treatment area ) . woman fertile age , patient type 1 diabetes mellitus severe endstage type 2 diabetes mellitus , diabetic retinopathy , atrial fibrillation , clinically significant anemia ( hemoglobin count &lt; 120 mg/l male , &lt; 110 mg/l female ; hematocrit &lt; 0.36 ) , leukopenia ( bleukocyte count &lt; 3.0x109/l ) , leukocytosis ( bleukocyte count &gt; 12.0x109/l ) thrombocytopenia ( bthrombocyte count &lt; 100x109/l ) , renal insufficiency ( screatinine &gt; 160mg/l ) , liver insufficiency ( salanine amino transferase salcaline phosphatase 2 x normal ) , haematuria unknown origin , severe hypertension ( systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 110 mmHg ) significant hypotension ( systolic blood pressure &lt; 90mmHg ) , significant obesity ( BMI &gt; 35 ) , cardiac pacemaker , acute infection , immunosuppressive medication , significant impairment leave ventricular function ( EF &lt; 25 % TTE CO &lt; 2 l MRI ) , congestive heart failure , haemodynamically significant ( gradus 34/4 ) aortic regurgitation heart disease need surgery , recent ( &lt; 6 week ) acute coronary syndrome myocardial infarction ( elevate CKMB cardiac troponin ) , PCI CABG TIA/stroke , previous current malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Refractory angina pectoris</keyword>
	<keyword>Vascular endothelial growth factor</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Perfusion</keyword>
</DOC>